E Zucca
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
Moccia A, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli S, Güsewell S, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr M, Fischer N, Ghilardi G, Krasniqi F, Hitz F. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. Hematol Oncol 2020; 39:196-204.
23.12.2020Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
23.12.2020Hematol Oncol 2020; 39:196-204
Moccia A A, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli Stefanie, Güsewell Sabine, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr Martin, Fischer N, Ghilardi G, Krasniqi F, Hitz Felicitas
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
Hitz F, Mey U, Zucca E, Berardi Vilei S, Eckhardt K, Berthod G, Caspar C, Pabst T, Fischer N, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol 2013; 92:1033-40.
17.04.2013Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
17.04.2013Ann Hematol 2013; 92:1033-40
Hitz F, Mey U, Zucca E, Berardi Vilei S, Eckhardt K, Berthod G, Caspar C, Pabst Th, Fischer N, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
02.02.2010Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
02.02.2010Br J Cancer 2010; 102:673-7
Jörger Markus, Huitema A D R, Krähenbühl S, Schellens J H M, Cerny Thomas, Reni M, Zucca E, Cavalli F, Ferreri A J M
Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4484.
01.01.2010Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
01.01.2010J Clin Oncol 2010; 28:4480-4484
Martinelli G, Zucca E, Dietrich P Y, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess Urs, Cerny Thomas, Utiger U, Schmitz S F, Ghielmini M
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
Hitz F, Ghielmini M, Zimmermann D, Bertoni F, Cogliatti S, Peterson J, Simcock M, Mingrone W, von Moos R, Zucca E, Martinelli G, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematological oncology 2009; 27:154-9.
01.09.2009A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
01.09.2009Hematological oncology 2009; 27:154-9
Hitz Felicitas, Ghielmini M, Zimmermann D R, Bertoni F, Cogliatti Sergio B., Peterson J, Simcock M, Mingrone W, von Moos R, Zucca E, Martinelli G, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland